Seres Therapeutics (MCRB) Misses Q1 EPS by 8c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Seres Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Updates
May 4, 2021 7:00 AM EDTTopline clinical data from SER-287 Phase 2b study in patients with mild-to-moderate ulcerative colitis expected in mid-2021, microbiome biomarker data anticipated in H2 2021
Ongoing enrollment in SER-109 open label study for recurrent C. difficile infection; On track to achieve 300 subject enrollment target in Q3 2021
Virtual ulcerative colitis microbiome therapeutic investor event to be held June 21, 2021
Conference call at 8:30 a.m. ET today
CAMBRIDGE, Mass.--(BUSINESS... More
